Risk of Coronavirus Disease 2019 Occurrence, Severe Presentation, and Mortality in Patients with Lung Cancer
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Purpose This study aimed to analyze whether patients with lung cancer have a higher susceptibility of coronavirus disease 2019 (COVID-19), severe presentation, and higher mortality than those without lung cancer. Materials and Methods A nationwide cohort of confirmed COVID-19 (n=8,070) between January 1, 2020, and May 30, 2020, and a 1:15 age-, sex-, and residence-matched cohort (n=121,050) were constructed. A nested case-control study was performed to compare the proportion of patients with lung cancer between the COVID-19 cohort and the matched cohort. Results The proportion of patients with lung cancer was significantly higher in the COVID-19 cohort (0.5% [37/8,070]) than in the matched cohort (0.3% [325/121,050]) (p=0.002). The adjusted odds ratio [OR] of having lung cancer was significantly higher in the COVID-19 cohort than in the matched cohort (adjusted OR, 1.51; 95% confidence interval [CI], 1.05 to 2.10). Among patients in the COVID-19 cohort, compared to patients without lung cancer, those with lung cancer were more likely to have severe COVID-19 (54.1% vs. 13.2%, p < 0.001), including mortality (18.9% vs. 2.8%, p < 0.001). The adjusted OR for the occurrence of severe COVID-19 in patients with lung cancer relative to those without lung cancer was 2.24 (95% CI, 1.08 to 4.74). Conclusion The risk of COVID-19 occurrence and severe presentation, including mortality, may be higher in patients with lung cancer than in those without lung cancer.
Abstract
Purpose This study aimed to analyze whether patients with lung cancer have a higher susceptibility of coronavirus disease 2019 (COVID-19), severe presentation, and higher mortality than those without lung cancer. Materials and Methods A nationwide cohort of confirmed COVID-19 (n=8,070) between January 1, 2020, and May 30, 2020, and a 1:15 age-, sex-, and residence-matched cohort (n=121,050) were constructed. A nested case-control study was performed to compare the proportion of patients with lung cancer between the COVID-19 cohort and the matched cohort. Results The proportion of patients with lung cancer was significantly higher in the COVID-19 cohort (0.5% [37/8,070]) than in the matched cohort (0.3% [325/121,050]) (p=0.002). The adjusted odds ratio [OR] of having lung cancer was significantly higher in the COVID-19 cohort than in the matched cohort (adjusted OR, 1.51; 95% confidence interval [CI], 1.05 to 2.10). Among patients in the COVID-19 cohort, compared to patients without lung cancer, those with lung cancer were more likely to have severe COVID-19 (54.1% vs. 13.2%, p < 0.001), including mortality (18.9% vs. 2.8%, p < 0.001). The adjusted OR for the occurrence of severe COVID-19 in patients with lung cancer relative to those without lung cancer was 2.24 (95% CI, 1.08 to 4.74). Conclusion The risk of COVID-19 occurrence and severe presentation, including mortality, may be higher in patients with lung cancer than in those without lung cancer.
참고문헌 (18)
- Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
- Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019novel coronavirus pneumonia in Wuhan, China : a descriptive study", Lancet, 395, pp.507~513 (2020)
- Wu Z, "Characteristics of and important lessons from the coronavirus disease 2019(COVID-19)outbreak in China : summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention", JAMA, 323, pp.1239~1242 (2020)
- Williamson EJ, "Factors associated with COVID-19-related death using OpenSAFELY", Nature, 584, pp.430~436 (2020)
- Garassino MC, "COVID-19 in patients with thoracic malignancies(TERAVOLT) : first results of an international, registry-based, cohort study", Lancet Oncol, 21, pp.914~922 (2020)
- Liang W, "Cancer patients in SARS-CoV-2 infection : a nationwide analysis in China", Lancet Oncol, 21, pp.335~337 (2020)
- Yu J, "SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China", JAMA Oncol, 6, pp.1108~1110 (2020)
- Alqahtani JS, "Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19 : a rapid systematic review and meta-analysis", PLoS One, 15, pp.e0233147~ (2020)
- Yang JM, "Allergic disorders and susceptibility to and severity of COVID-19 : a nationwide cohort study", J Allergy Clin Immunol, 146, pp.790~798 (2020)
- Grasselli G, "Critical care utilization for the COVID-19 outbreak in Lombardy, Italy : early experience and forecast during an emergency response", JAMA, 323, pp.1545~1546 (2020)
- Yang X, "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China : a single-centered, retrospective, observational study", Lancet Respir Med, 8, pp.475~481 (2020)
- Rogado J, ". Covid-19 and lung cancer: a greater fatality rate?", Lung Cancer, 146, pp.19~22 (2020)
- Luo J, "COVID-19 in patients with lung cancer", Ann Oncol, 31, pp.1386~1396 (2020)
- "National Health Insurance Sharing Service" (2019)[URL]
- Reynolds HR, "Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19", N Engl J Med, 382, pp.2441~2448 (2020)
- Choi H, "Population-based prevalence of bronchiectasis and associated comorbidities in South Korea", Eur Respir J, 54, pp.1900194~ (2019)
- Grasselli G, "Baseline characteristics and outcomes of 1591patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy", JAMA, 323, pp.1574~1581 (2020)
- Song J, "Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19", Allergy, 76, pp.483~496 (2021)